Replimune Group, Inc. (NASDAQ:REPL) Short Interest Down 16.5% in November

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 5,580,000 shares, a decrease of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily volume of 828,800 shares, the days-to-cover ratio is presently 6.7 days.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. Millennium Management LLC boosted its stake in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after purchasing an additional 2,656,173 shares during the period. Braidwell LP boosted its position in Replimune Group by 203.0% in the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company's stock valued at $33,656,000 after buying an additional 2,057,460 shares during the period. State Street Corp grew its stake in shares of Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock worth $25,647,000 after acquiring an additional 1,182,181 shares in the last quarter. Baker BROS. Advisors LP increased its position in shares of Replimune Group by 10.0% during the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company's stock worth $121,057,000 after acquiring an additional 1,000,000 shares during the period. Finally, Parkman Healthcare Partners LLC raised its stake in shares of Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company's stock valued at $8,371,000 after acquiring an additional 238,747 shares in the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on REPL shares. Roth Capital raised Replimune Group to a "strong-buy" rating in a report on Tuesday, August 27th. HC Wainwright reiterated a "buy" rating and set a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd. BMO Capital Markets boosted their price target on shares of Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a research report on Friday, November 22nd. Jefferies Financial Group raised their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Replimune Group has an average rating of "Buy" and a consensus price target of $17.29.

Replimune Group Trading Up 2.7 %

Replimune Group stock traded up $0.33 during trading on Friday, hitting $12.55. The company had a trading volume of 596,389 shares, compared to its average volume of 1,048,577. The stock has a market cap of $858.67 million, a price-to-earnings ratio of -4.11 and a beta of 1.26. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The company's 50 day simple moving average is $12.19 and its 200-day simple moving average is $10.49.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, analysts expect that Replimune Group will post -2.91 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.